For cardiovascular-outcome work, semaglutide wins on the deepest evidence base (SELECT trial)
Tirzepatide is not recommended for people with a family history of thyroid tumors or a family history of medullary thyroid carcinoma (MTC) and MEN2 syndrome (multiple endocrine neoplasia type 2 syndrome), as tirzepatide increases the potential risk of developing these tumors in rodents
Graphical Abstract Similar content being viewed by others Introduction Simultaneous management of glucose levels, lipid profile, BP and body weight is essential for preventing chronic complications in type 2 diabetes and has been consistently associated with a reduction in incident cardiovascular events [1,2,3,4,5]
The Ozempic SmPC recommends starting at 0.25 mg weekly for 4 weeks (for tolerability), then increasing to 0.5 mg weekly, with further escalation as clinically indicated
Add a small amount of difficulty every 23 weeks one more repetition, a slightly heavier band, or a more challenging variation of the exercise
